Because VEGF inhibition often leads to proteinuria and renal thrombotic microangiopathy [41], VASH2 is likely to be a superior target for anti-angiogenic therapy in diabetic nephropathy, similar to cancers [18]. The gene discussed is VASH2; the disease is cancer.